Added anti-viral improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news160275409.html">Added anti-viral improves response, halves duration of hepatitis C treatment</a></p> <p>The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).</p>